Clinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis
A Phase Ib, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study of the Clinical Effect, Safety and Tolerability of a Single Intravenous Infusion of GSK1070806 in Moderate to Severe Atopic Dermatitis Patients
Sponsor: GlaxoSmithKline
A PHASE1 clinical study on Dermatitis, Atopic, this trial is completed. The trial is conducted by GlaxoSmithKline and has accumulated 10 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Completed PHASE1
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Feb 2023 — Sep 2023 [monthly]
Active Not Recruiting PHASE1
-
Nov 2022 — Feb 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2022 — Nov 2022 [monthly]
Recruiting PHASE1
-
Feb 2022 — Jul 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .